CrowdStrike Holdings Stock (NASDAQ: CRWD)

Dernières nouvelles pour CrowdStrike Holdings (NASDAQ:CRWD) Stock

CrowdStrike Holdings

CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.

CrowdStrike Holdings, Inc. - Class A Common Stock

CrowdStrike Holdings Inc

WIIM

NVDA

Nvidia shares are trading lower after Huawei announced it's preparing a new AI chip as an alternative to Nvidia. Additionally, deteriorating US-China trade relations continues to weigh on the stock

Raymond James analyst Buck Horne upgrades Center (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSR#NYSE">CSR</a>) from Market Perform to Outperform and announces $66 price target.

News

Upgrades

Price Target

Analyst Ratings

Raymond James Upgrades Center to Outperform, Announces $66 Price Target

Billionaire Entrepreneur Mark Cuban recently expressed his thoughts on tariffs, artificial intelligence (AI), robotics, and the potential for a recession in a recent interview.
What Happened: In&nbsp;a discussion with Iman Hasan of Biohack-it on Friday, Cuban stated that he is not against tariffs, but emphasized their strategic application. He argued that protecting certain sectors like farming or steel is acceptable, but cautioned against blanket tariffs due to their inflationary impact. He also stressed that manufacturing industries won&#8217;t bounce back instantly, as it&#8217;s a process that takes years.
The Shark Tank celebrity suggested that the U.S. should have first established industries domestically, leveraging&nbsp;AI and robotics to compete&nbsp;on a global scale, and then used tariffs as a negotiation tool. He warned that the current situation is akin to&nbsp;a game of chicken with&nbsp;China, a country that lends the U.S. trillions, but also relies on it as a major market. Overplaying the hand or resource restriction from China could lead to detrimental effects.
&#8220;And so it&#8217;s a game of chicken and you know I don&#8217;t know what China&#8217;s going to,&#8221; stated Cuban as he cited how China is imposing restrictions on natural resources and rare earths to keep the U.S. from manufacturing things. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Mark Cuban on Trump's Tariffs, Elon Musk, and Biggest Shark Tank Regrets" width="500" height="281" src="https://www.youtube.com/embed/5uOTYZvaVKA?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Cuban further explained that having a trade deficit with China isn&#8217;t such a bad thing for the U.S. and it means we are a large consumer market. On the other hand, U.S. has a trade surplus with China in services and if the latter puts tariffs on those services, stops lending money to the U.S or stop buying the U.S. agricultural produce, it could lead to a great problem. 
Cuban further stated, &#8220;Donald Trump has been dogmatic about trade for 30 plus years&#8221; adding that &#8220;you can&#8217;t be dogmatic in business or government.&#8221;
When asked about the possibility of a recession similar to 2008, Mark Cuban considered it plausible but not guaranteed. He pointed out that tariffs,&nbsp;DOGE cuts, and isolationism could&nbsp;lead to stagflation if federal&nbsp;spending significantly reduces GDP. However, he noted that unlike the financial errors of 2008, this situation is driven by policy, which can be quickly altered if perspectives change.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/04/44891949/chinese-commerce-ministry-pledges-retaliation-against-countries-isolating-beijing-with-us-at-the-expense-of-china" target="_blank" rel="noreferrer noopener">Xi Jinping&#8217;s China Pledges Retaliation Against Countries Isolating Beijing By Giving Into Trump Administration&#8217;s &#8216;Unilateral Bullying,&#8217; Says It Will &#8216;Never Accept It&#8217;</a>
Why It Matters: Mark Cuban&#8217;s views on tariffs are not new. Earlier this month, he <a href="https://www.benzinga.com/personal-finance/25/04/44702876/mark-cuban-predicts-tariffs-will-make-things-ugly-for-amazon-but-incredible-for-american-sellers-but-some-point-out-they-all-source-from-china">predicted </a>that tariffs would make things &#8216;ugly for Amazon, but incredible for American sellers&#8217;, highlighting the potential impact on e-commerce giant Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
A week later, Mark criticized <a href="https://www.benzinga.com/news/25/04/44786027/mark-cuban-criticizes-tariff-supporters-who-dont-buy-american-you-are-a-hypocrite">tariff supporters </a>who don&#8217;t buy American, calling them hypocrites. He argued that if people were advocating for tariffs to bring manufacturing and jobs back to the U.S., they should be exclusively buying American-made products.
These past statements provide context to Mark&#8217;s recent comments, demonstrating his consistent stance on the strategic application of tariffs and the importance of domestic industry development.
That being said, during the interview, the billionaire expressed support for some of Trump&#8217;s policies like the handling of border issues, the Make America Healthy Again (MAHA) initiative and the sale of the Gold visa cards. Last week, he also hailed Trump&#8217;s executive order on <a href="https://www.benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">drug pricing</a> and said it could save billions. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/general/biotech/25/04/44892867/elon-musk-says-neuralink-will-help-blind-people-see-again-will-exceed-the-best-human-eyes" target="_blank" rel="noreferrer noopener">Elon Musk Says Neuralink Will Help Blind People See Again: &#8216;Will Exceed The Best Human Eyes&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

AMZN

Mark Cuban Says 'It's A Game Of Chicken' With China As He Questions Trump's Strategy Behind Tariffs: 'You Can't Be Dogmatic In Business Or Government'

<a href="https://www.reuters.com/world/china/india-put-12-temporary-tariff-steel-curb-cheap-china-imports-source-says-2025-04-21/">https://www.reuters.com/world/china/india-put-12-temporary-tariff-steel-curb-cheap-china-imports-source-says-2025-04-21/</a>
&nbsp;
India is set to impose a temporary tariff, known locally as safeguard duty, of 12% on steel imports, said a government source with direct knowledge of the matter, to try and curb a surge in cheap imports from China and elsewhere.
The government would enact the tax as soon as possible, the source, who did not wish to be named, told Reuters on Monday.

Global

Trading Ideas

INDA

STLD

Reported Earlier, 'India To Put 12% Temporary Tariff On Steel To Curb Cheap China Imports, Source Says' - Reuters News

COYA 303 is an investigational biologic combination of COYA 301, Coya's low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory therapeutic in autoimmune and neurodegenerative diseases
COYA 303 produced a statistically significantly higher Treg suppressive effect on pro-inflammatory myeloid cells and enhanced Treg survival in in vitro human immune cells, compared to the individual components - LD IL-2 and GLP-1RA
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.coyatherapeutics.com&amp;esheet=54240991&amp;newsitemid=20250421341942&amp;lan=en-US&amp;anchor=Coya+Therapeutics%2C+Inc.&amp;index=1&amp;md5=2d10b2fb8571b069c4252d7aefb67cee">Coya Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced publication of the results of a study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA), Coya's investigational biologic combination to suppress pro-inflammatory myeloid cells, enhance Treg suppressive function, and modulate T cell proliferation, in an in vitro system of human immune cells obtained from healthy donors. The research was conducted at the Houston Methodist Research Institute and was led by Dr. Aaron Thome and Dr. Stan Appel. The research article has been published in the Journal NeuroImmune Pharmacology and Therapeutics and can be accessed <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.degruyterbrill.com%2Fdocument%2Fdoi%2F10.1515%2Fnipt-2025-0001%2Fhtml&amp;esheet=54240991&amp;newsitemid=20250421341942&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=1c68d4785995b3193e0bc20c206167c1">here</a>.

COYA

Coya Therapeutics Announces Publication of COYA 303 Combination Biologic Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Cell Death

Wells Fargo analyst Hanwen Chang maintains Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) with a Overweight and lowers the price target from $51 to $48.

VNOM

Wells Fargo Maintains Overweight on Viper Energy, Lowers Price Target to $48

Wells Fargo analyst Colin Langan maintains Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) with a Equal-Weight and lowers the price target from $397 to $308.

Wells Fargo Maintains Equal-Weight on Lithia Motors, Lowers Price Target to $308

General

Haoxi Health Technology Reveals Customized Livestreaming Agency Strategy

Wells Fargo analyst Colin Langan maintains AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) with a Equal-Weight and lowers the price target from $194 to $176.

Wells Fargo Maintains Equal-Weight on AutoNation, Lowers Price Target to $176

Bitcoin reclaimed the $80,000 level before last week&#8217;s candle closed, but there&#8217;s still a lot of uncertainty in the markets. Major headlines—especially those related to the ongoing trade war between the US and China—could increase volatility.
Tariffs have been the main driver of volatility in the markets over the past few weeks. Any mention of tariffs has caused the markets to move in either direction. The key headline to watch in the coming weeks, as the trade war continues to unfold, is how China responds. This will be the primary focus for traders, as it's what most are paying attention to.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Weekly Chart
When it comes to the weekly chart, there are a few key levels I would monitor to help paint the bigger picture. As I've discussed in previous write-ups, the main level for Bitcoin to find support is the prior swing low, which sits around $76,000–$78,000.
Last week, we saw a retest of that level, and buyers stepped in, resulting in a strong weekly close back inside the trading range.
This is a great start to see potential upside, but the key word to remember is continuation. Bitcoin had a strong reaction, but without continuation or clean follow-through, it doesn&#8217;t mean much for traders.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Daily Chart
Zooming into the daily chart, we can see our levels in more detail. Looking at the range low, we saw how price initially found support at that level before breaking below, retesting it, and continuing lower.
This is a level you'll want to monitor, as past price action has shown rejection around the low 90Ks. While this doesn't guarantee that price will reject at this level again, it's important to observe how price behaves there and what unfolds.
The daily structure is still technically semi-bearish, as the market has yet to make a clear higher high. The bullish case for Bitcoin would be to hold above $76,000, with last week marking a significant low that could start a potential move back up toward the range lows.
From there, depending on how price reacts—since pullbacks are likely—the key will be whether the market forms a higher low, which would provide confirmation of a potential trend shift and a move back toward all-time highs.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li><a href="https://www.benzinga.com/money/investing-in-the-midwest-why-multifamily-real-estate-is-a-winning-strategy">This investment company boasts a 33.85% internal rate of return (IRR) for its realized projects, allowing accredited investors to earn passive returns and avoid the headaches of being a landlord.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Bitcoin Holds $80K: 3 Key Levels That Will Make or Break This Rally

LXEH

Lixiang Education Shares Halted On Circuit Breaker To The Downside, Stock Now Down -66.5%

W. R. Berkley Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/wrb/earnings">closing bell on Monday, April 21.</a>
Analysts expect the Greenwich, Connecticut-based company to report quarterly earnings at 99 cents per share, down from $1.04 per share in the year-ago period. W. R. Berkley projects to report quarterly revenue at $3.02 billion, compared to $2.76 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 28, W. R. Berkley confirmed that Japan&#8217;s Mitsui Sumitomo Insurance (MSI) will acquire a 15% stake through a newly announced investment and voting agreement.
W. R. Berkley shares rose 0.5% to close at $68.80 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/wrb/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Jefferies analyst Yaron Kinar maintained a Hold rating and raised the price target from $57 to $66 on April 11, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Meyer Shields maintained a Market Perform rating and slashed the price target from $64 to $62 on April 9, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Wells Fargo analyst Elyse Greenspan downgraded the stock from Overweight to Equal-Weight and cut the price target from $70 to $69 on April 9, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Truist Securities analyst Mark Hughes maintained a Buy rating and increased the price target from $68 to $80 on April 3, 2025. This analyst has an accuracy rate of 84%.</li>
<li>B of A Securities analyst Joshua Shanker downgraded the stock from Buy to Neutral and increased the price target from $73 to $74 on April 1, 2025. This analyst has an accuracy rate of 75%.</li>
</ul>
Considering buying WRB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="609" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21015632/image-28-1024x609.png" alt="" class="wp-image-878922" style="width:520px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21015632/image-28-1024x609.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21015632/image-28-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21015632/image-28-768x456.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21015632/image-28.png 1077w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Earnings

Pre-Market Outlook

Top Wall Street Forecasters Revamp W. R. Berkley Expectations Ahead Of Q1 Earnings

WIMI

WiMi Hologram Shares Halted On Circuit Breaker To The Upside, Stock Now Up 23.1%

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are trading lower Monday following reports that the company has postponed plans for an affordable version of its <a href="https://www.benzinga.com/25/04/44888254/elon-musks-tesla-delays-launch-of-affordable-model-y-by-several-months-report">Model Y SUV</a>.
What To Know: According to a Reuters report citing three sources with knowledge of the matter, Tesla has delayed the launch of a U.S.-made, stripped-down version of its Model Y that was originally planned for the first half of the year. 
The report indicates that production of the lower-cost version of the Model Y, codenamed E41 internally, is expected to begin at least a few months later than Tesla previously forecasted. New timelines suggest the affordable model could enter production sometime between the third quarter and early next year. 
People familiar with the matter reportedly said Tesla was aiming to produce 250,000 stripped-down Model Ys in the U.S. in 2026. The company also plans to produce the vehicle in China and Europe eventually. The vehicle is expected to cost about 20% less to make than the latest refreshed version.
The sources didn&#8217;t provide a reason for the delay, but the news comes amid rising global trade tensions following the Trump administration&#8217;s sweeping reciprocal tariffs on a slew of nations. 
The report also indicates that Tesla is planning to launch a basic version of its Model 3 sedan. CEO Elon Musk previously said the company would offer vehicles priced as low as $25,000, but he suggested the company had shifted its focus to robotaxi development instead during the company&#8217;s third-quarter earnings call. 
"I think having a regular $25,000 model is pointless. Yeah, it would be silly,&#8221; Musk <a href="https://www.benzinga.com/markets/equities/24/10/41507504/elon-musk-shuts-down-traditional-tesla-25k-ev-rumors-calls-it-pointless-as-company-focuses-on-al">said on the call</a>. 
Check This Out: <a href="https://www.benzinga.com/25/04/44896337/teslas-q1-test-drive-will-earnings-steer-tesla-stock-out-of-the-ditch">Tesla Q1 Test Drive: Will Earnings Steer The Stock Out Of The Ditch?</a>
Tesla is due to report <a href="https://www.benzinga.com/calendars/earnings">first-quarter financial results</a> after the market close on Tuesday. Analysts expect the EV maker to report earnings of 41 cents per share and revenue of $21.35 billion, according to estimates from<a href="http://pro.benzinga.com"> Benzinga Pro</a>. 
Tesla reported its first decline in annual deliveries at the beginning of the year. Analysts expect annual sales to decline again in 2025 for multiple reasons, including potential brand damage related to Musk&#8217;s close ties to the Trump administration.
Automakers are facing higher prices and potential supply-chain disruptions due to tariffs. Reuters reported that Tesla has ramped up North American parts sourcing in recent years, which could lower tariff exposure for the lower-cost Model Y, known internally as E41. 
TSLA Price Action: <a href="http://benzinga.com/quote/TSLA">Tesla shares</a> were down 5.29% at $228.45 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44894382/tesla-battery-supplier-catl-unveils-new-fast-charging-battery-with-323-mile-range-in-five-minutes">Tesla Battery Supplier CATL Unveils New Fast-Charging Battery With 323-Mile Range In Five Minutes</a></li>
</ul>
Photo: courtesy of Tesla.

Movers

TSLA

Tesla Stock Is Sliding Monday: What's Driving The Action?

Lixiang Education Shares Resume Trading

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $182 to $110.

SRPT

Piper Sandler Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $110

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2)
Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer
RARITAN, N.J., April 21, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas. Among the highlights are the 12-month duration of response (DOR) data from the Phase 2b Cohort 2 SunRISe-1 study, evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with Bacillus Calmette-Guérin (BCG)—unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) with or without papillary disease. These findings will be featured in the Practice-changing, Paradigm-shifting Clinical Trials in Urology&nbsp;plenary session on Saturday, April 26.
A second plenary presentation will feature first&nbsp;results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200 monotherapy in patients with BCG–unresponsive, papillary-only HR-NMIBC. In this patient population, bladder removal remains a standard treatment, but many patients are elderly, have significant comorbidities, or are unwilling to undergo radical surgery, making treatment challenging.

Johnson & Johnson Says First Results From Cohort 4 Of Phase 2B Sunrise-1 Study Show Potential Of TAR-200 Monotherapy In Patients With Papillary-only, High-risk Non-muscle Invasive Bladder Cancer

MLGO

MicroAlgo Shares Halted On Circuit Breaker To The Upside, Stock Now Up 56%

<a href="https://www.bloomberg.com/news/articles/2025-04-21/air-india-keen-to-take-boeing-planes-refused-by-chinese-airlines">https://www.bloomberg.com/news/articles/2025-04-21/air-india-keen-to-take-boeing-planes-refused-by-chinese-airlines</a>

'Air India Keen To Take Boeing Planes Refused By Chinese Airlines'- Bloomberg

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2)
Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer
RARITAN, N.J., April 21, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas. Among the highlights are the 12-month duration of response (DOR) data from the Phase 2b Cohort 2 SunRISe-1 study, evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with Bacillus Calmette-Guérin (BCG)—unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) with or without papillary disease. These findings will be featured in the Practice-changing, Paradigm-shifting Clinical Trials in Urology&nbsp;plenary session on Saturday, April 26.

Johnson & Johnson Says TAR-200 Monotherapy Shows Highest Complete Response With Sustained Benefits In 12-month Data From Phase 2B SunRISe-1 Study (Cohort 2)

Press Releases

NTT DATA and CrowdStrike Expand Partnership to Strengthen AI-Powered Cyber Resilience

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CrowdStrike Holdings, Inc. - CRWD

CrowdStrike Collaborates with NVIDIA to Advance Agentic AI in Cybersecurity, Pioneer Testing of NVIDIA Reasoning Models

CrowdStrike Earns FedRAMP High Authorization to Protect U.S. Government and National Security Operations

CrowdStrike Accelerates Cybersecurity Consolidation with AI-Powered Network Vulnerability Assessment for Falcon Exposure Management

CrowdStrike Announces Services Partner Program to Transform the SOC, Accelerating Ecosystem Growth with Falcon® Next-Gen SIEM

CrowdStrike Recognizes 2025 Americas Partner Award Winners at Annual Partner Symposium

CrowdStrike Appoints Alex Ionescu as Chief Technology Innovation Officer

CrowdStrike Wins 2025 Google Cloud Security Partner of the Year Award in the Workload Security Category; Expands Partnership to Secure AI Innovation

Legal

CROWDSTRIKE ALERT: Bragar Eagel & Squire, P.C. is Investigating CrowdStrike Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

CrowdStrike Holdings

Actualités

Dernières nouvelles pour CrowdStrike Holdings (NASDAQ:CRWD) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL